Efficacy of immunosuppression monotherapy after liver transplantation: A meta-analysis

Table 2 Methodological quality of including randomized cohort studies

Ref.	Selection criteria specified	Study design	Jadad scale score	Other causing of death report	Dropouts explained	Funding
Benítez et al[18]	Adequate	RCT	4	Adequate	Yes	Supported by grants from Fresenius Biotech GmbH, Spain
Boillot et al[19]	Adequate	RCT	4	Adequate	Adequate	Supported by Fujisawa GmbH, Munich, Germany
Weiler et al[20]	Adequate	RCT	3	Adequate	Adequate	NS
Chau et al[21]	Adequate	RCT	3	NS	NS	NS
Moench et al[22]	Adequate	RCT	6	Adequate	Adequate	Supported by Astellas Pharma Munich, Germany
Eason et al[23]	Adequate	RCT	4	NS	Adequate	Supported by unrestricted educational grants from Sangstat and Fujisawa
Samonakis et al[12]	Adequate	RCT	3	NS	Ns	Support from Fujisawa for some of the personnel involved in this investigator-led study
Margarit et al[13]	Adequate	RCT	4	Adequate	Adequate	Supported, in part, by a grant from Fujisawa GM
Manousou et al[14]	Adequate	RCT	6	Adequate	Adequate	NS
Belli et al[24]	Adequate	RCT	3	Adequate	Adequate	NS
De Carlis et al[25]	Adequate	RCT	4	Adequate	Adequate	NS
Romani et al[26]	Adequate	RCT	4	Adequate	Adequate	NS
Schlitt et al[27]	Adequate	RCT	4	Adequate	Adequate	NS
Schmeding et al[28]	Adequate	RCT	4	Adequate	Adequate	Funding for patient monitoring and laboratory diagnostics and data analysis was partially provided by Roche Pharmaceutical Company, Grenzach-Wyhlen, Germany

RCT: Randomized cohort studie; NS: Not significant.